ciglitazone has been researched along with Pneumonia in 2 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ciglitazone ameliorates the inflammatory response and may reduce lung injury after hemorrhagic shock." | 7.74 | Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. ( Chima, RS; Denenberg, A; Hake, PW; Mangeshkar, P; Piraino, G; Zingarelli, B, 2008) |
| "Ciglitazone ameliorates the inflammatory response and may reduce lung injury after hemorrhagic shock." | 3.74 | Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock. ( Chima, RS; Denenberg, A; Hake, PW; Mangeshkar, P; Piraino, G; Zingarelli, B, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chima, RS | 1 |
| Hake, PW | 1 |
| Piraino, G | 1 |
| Mangeshkar, P | 1 |
| Denenberg, A | 1 |
| Zingarelli, B | 1 |
| Ward, JE | 1 |
| Fernandes, DJ | 1 |
| Taylor, CC | 1 |
| Bonacci, JV | 1 |
| Quan, L | 1 |
| Stewart, AG | 1 |
2 other studies available for ciglitazone and Pneumonia
| Article | Year |
|---|---|
Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock.
Topics: Animals; Blood Glucose; Chemokines; Cytokines; Disease Models, Animal; Immunohistochemistry; Inflamm | 2008 |
The PPARgamma ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation.
Topics: Allergens; Animals; Bronchoalveolar Lavage Fluid; Bronchoconstrictor Agents; Disease Models, Animal; | 2006 |